Tonix Pharmaceuticals
TNXP
$19.64 0.56%
Exchange: NASDAQ | Sector: Healthcare | Industry: Biotechnology
Q4 2024
Published: Mar 18, 2025

Earnings Highlights

  • Revenue of $2.58M down 31.7% year-over-year
  • EPS of $-976.72 decreased by 3% from previous year
  • Gross margin of 54.2%
  • Net income of -22.11M
  • ""We believe that our ongoing investment in R&D will be pivotal in unlocking new value."" - CEO
TNXP
Tonix Pharmaceuticals Holding Corp

Executive Summary

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) reported disappointing Q4 2024 results, with a net loss of $22.1 million and revenues of $2.58 million, reflecting a 31.68% decline year-over-year. This comes as the company continues to grapple with high research and development expenditures, amounting to $8.3 million, significantly impacting profitability. The management emphasized ongoing efforts to stabilize costs and streamline operations, while also highlighting upcoming projects aimed at diversifying and enhancing their therapeutic portfolio. Overall, investors face a challenging landscape as Tonix strives to reverse its recent revenue decline amid competitive pressures and operational hurdles.

Key Performance Indicators

Revenue
Decreasing
2.58M
QoQ: -8.50% | YoY: -31.68%
Gross Profit
Increasing
1.40M
54.18% margin
QoQ: 10.42% | YoY: 1 870.89%
Operating Income
Increasing
-22.48M
QoQ: -44.53% | YoY: 17.74%
Net Income
Increasing
-22.11M
QoQ: -55.55% | YoY: 19.08%
EPS
Decreasing
-976.72
QoQ: -424 560.87% | YoY: -3 447.84%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q4 2024 2.58 -976.72 -31.7% View
Q3 2024 2.82 -0.23 -29.3% View
Q2 2024 2.21 -19.28 +0.0% View
Q1 2024 2.48 -5.91 -92.7% View
Q4 2023 3.78 -27.53 +0.0% View